Fight disinformation. Get a daily recap of the facts that matter. Sign up for the free Mother Jones newsletter.


On October 21, 1993, Drs. Mitchell Creinin and Phillip Darney of the University of California at San Francisco publicized the results of their study of methotrexate as an abortifacient. The study, published in the journal Contraception, involved ten women, eight of whose pregnancies were successfully terminated. (Since the original study, more than fifty women have undergone the experimental procedure.)

The most significant aspect of the UCSF study, according to Nancy Tompkins, editor of the pro-choice newsletter Choosing Choice, is the fact that methotrexate is already on the market and FDA-approved for other purposes. Before its use as an abortifacient can be anything other than experimental, however, someone has to apply for a “supplemental indication” approval, which is generally easier to get than a new-drug approval.

Others are less optimistic than Tompkins. Thus far, no drug company has publicly requested a supplemental indication approval, and according to Wayne Koberstein, editor of Pharmaceutical Executive, “it is very unlikely that any large brand-name company will take this on.” Ironically, what may prevent methotrexate from becoming widely available for abortion is its low cost (four dollars per dose compared to two hundred dollars for RU 486). Because of this, methotrexate is unlikely to be a big profit-maker, and companies may be unwilling to risk the wrath of antiabortion groups by marketing it. Even if a company does take this chance, the drug’s approval is probably at least one or two years away.

HERE ARE THE FACTS:

Our fall fundraising drive is off to a rough start, and we very much need to raise $250,000 in the next couple of weeks. If you value the journalism you get from Mother Jones, please help us do it with a donation today.

As we wrote over the summer, traffic has been down at Mother Jones and a lot of sites with many people thinking news is less important now that Donald Trump is no longer president. But if you're reading this, you're not one of those people, and we're hoping we can rally support from folks like you who really get why our reporting matters right now. And that's how it's always worked: For 45 years now, a relatively small group of readers (compared to everyone we reach) who pitch in from time to time has allowed Mother Jones to do the type of journalism the moment demands and keep it free for everyone else.

Please pitch in with a donation during our fall fundraising drive if you can. We can't afford to come up short, and there's still a long way to go by November 5.

payment methods

ONE MORE QUICK THING:

Our fall fundraising drive is off to a rough start, and we very much need to raise $250,000 in the next couple of weeks. If you value the journalism you get from Mother Jones, please help us do it with a donation today.

As we wrote over the summer, traffic has been down at Mother Jones and a lot of sites with many people thinking news is less important now that Donald Trump is no longer president. But if you're reading this, you're not one of those people, and we're hoping we can rally support from folks like you who really get why our reporting matters right now. And that's how it's always worked: For 45 years now, a relatively small group of readers (compared to everyone we reach) who pitch in from time to time has allowed Mother Jones to do the type of journalism the moment demands and keep it free for everyone else.

Please pitch in with a donation during our fall fundraising drive if you can. We can't afford to come up short, and there's still a long way to go by November 5.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate